BillionToOne, Inc. (BLLN)
BillionToOne, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Menlo Park, CA, US. The stock last traded at $113.89, up 3.11% on the session, giving a market capitalisation of $5.37B. On trailing twelve-month figures it carries a trailing P/E of 110.96, a net margin of 11.3%. Its beta of 0.34 implies it has historically moved less than the broad market.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
BillionToOne, Inc. is most often compared with the following Healthcare names: